At the University of Malaga, researchers have designed a one-two punch against SARS-CoV-2—combining peptide inhibitors with a mutagenic compound that forces the virus toward what scientists call "error catastrophe," a state of near-complete loss of infectivity. The discovery, published in Antimicrobial Agents and Chemotherapy, emerged from Sergio Ortega del Campo's doctoral research and represents a fundamentally new way of thinking about how to disable viruses that threaten global health.
The approach matters because conventional antivirals typically target one mechanism at a time—blocking replication or suppressing immune evasion. But viruses are adaptable adversaries, mutating their way around single-drug strategies. This dual-action treatment changes the game by attacking simultaneously on two fronts, leaving the pathogen nowhere to hide.
The strategy works like this: Ana Grande, a professor at the Department of Cell Biology, Genetics and Physiology, and her team designed small protein fragments that block key viral proteins essential for both genetic replication and immune escape. Simultaneously, they deployed 5-fluorouracil, a mutagenic compound that deliberately introduces errors during viral genome copying. Alone, each mechanism weakens the virus. Combined, they create a synergistic effect so powerful that the virus cannot recover. "While the peptides hinder replication, the compound increases the accumulation of mutations that leads the virus to a situation of 'error catastrophe' achieving near-complete loss of infectivity," Grande explains.
What makes this innovation particularly striking is what happens to the virus's genetic structure. The combined treatment doesn't just reduce viral load—it radically destabilizes the entire viral population by shrinking its genetic diversity. The virus replicates less efficiently while simultaneously accumulating mutations until it reaches a point of non-viability. It's a two-pronged assault that collapses both function and adaptability at once.
The research also holds promise far beyond COVID-19. The viral proteins targeted by the peptides are highly conserved across different coronavirus species, suggesting this strategy could evolve into a broad-spectrum antiviral capable of tackling emerging variants and related pathogens. In a world where new coronaviruses keep appearing, that flexibility could prove invaluable.
This work emerged from a genuinely multidisciplinary collaboration spanning institutions across Spain—including IBIMA Platforma BIONAND, Hospital Universitario Virgen de la Victoria, universities in Madrid and Miguel Hernández, and the Severo Ochoa Molecular Biology Center. The team moved from computational design through to experimental validation in cell cultures, building confidence in the approach's underlying logic.
Though the current work is confined to laboratory cell cultures, the researchers are already thinking bigger. They've filed for a patent to protect the therapeutic approach, signaling serious intent to move toward clinical development. That protective step suggests confidence that this dual-action strategy could eventually make the leap from the bench to real-world treatment.
For millions who have experienced COVID-19, and for the scientists who continue hunting variants, this work offers something worth following: a reminder that even formidable pathogens have vulnerabilities—and sometimes the answer lies not in hitting them harder, but in hitting them twice, from angles they cannot escape.